GlaxoSmithKline News and Research

RSS

POZEN enters Settlement Agreement with Teva over generic Treximet ANDA patent infringement litigation

POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.

15 Apr 2010

Opinions divided on swine flu fear

According to health experts the swine flu pandemic is far from over and remains a threat to the population, especially the young. John Mackenzie, the Australian who heads the World Health Organization’s independent but secretive Emergency Committee said in a statement on Wednesday, “This is just as severe as we saw in 1957 and 1968, with one major difference. We are not seeing deaths in the elderly but we are seeing them in a more important group of the population, healthy young adults… It is much more severe than people tend to talk about.”

15 Apr 2010

Drug company payments to doctors: Continuing controversy

The New York Times has two stories on pharmaceutical industry payments to physicians and experts.

15 Apr 2010

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Has the NHS procured too many swine flu shots?

Britain’s National Health Service (NHS) has nearly 34 million unused swine flu vaccines at present due to a drop in the number of cases and these vaccinations. A total 44 million shots were procured. 3.8 million of these unused shots will be sent to Africa via the World Health Organization to help them. Of the rest, 10.6m is already with GPs who will be ready to act if more people entitled to the jab come forward. But the remaining 23.6m will be held in reserve.

7 Apr 2010

Crucell, GSK sign agreement to develop 'second generation malaria vaccine'

Crucell, the Dutch biotechnology company, "said on Tuesday it had agreed with Britain's GlaxoSmithKline to jointly develop a malaria vaccine candidate, without disclosing financial details," Reuters reports (Gray-Block, 4/6).

7 Apr 2010

Premature fall in the swine flu vaccination rates worries health officials

Last fall there was a mad rush for the HINI vaccine for the deadly swine flu that had gripped countries across the world. H1N1 flu has killed about 12,000 Americans and put 265,000 into the hospital in the last pandemic. This year has seen a few signs of seasonal flu, which kills about 36,000 people in the United States each year and puts 200,000 in the hospital.

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Pfizer admits paying $35 million to doctors over last 6 months

Pfizer among other large pharmaceutical companies recently disclosed payments to doctors and other medical professionals for consulting and speaking on its behalf and also some sponsorship of clinical trials. On Wednesday in an announcement the company spokesperson revealed that they had paid a whopping $20 million to 4,500 doctors and other medical professionals in the last six months of 2009. Pfizer also accepted that they paid $15.3 million to 250 academic medical centers and other research groups for clinical trials in the same period. This disclosure is only about payments made within the US.

1 Apr 2010

Symyx Technologies forms alliance with Pistoia Alliance

Symyx Technologies, Inc. today announced it has joined the Pistoia Alliance, a non-profit group that promotes collaboration to streamline non-competitive elements of pharmaceutical and life science discovery workflows. The alliance was initially formed by major global pharmaceutical companies including Pfizer, GlaxoSmithKline, Novartis, and AstraZeneca.

1 Apr 2010

Dutasteride reduces risk of prostate cancer

There is good news for those at high risk for prostate cancer. The drug dutasteride which is manufactured by GlaxoSmithKline as the drug Avodart, has been found to reduce the risk of prostate cancer by a quarter. The drug is at present being used to treat enlarged prostates.

1 Apr 2010

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

GlaxoSmithKline and Isis Pharmaceuticals, Inc. announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness.

31 Mar 2010

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

The American Academy of Neurology (AAN) is awarding the 2010 Dreifuss-Penry Epilepsy Award to Martin J. Gallagher MD, PhD, with Vanderbilt University School of Medicine. Gallagher will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

30 Mar 2010

GSK offers free vaccines for low income adults without insurance coverage

GlaxoSmithKline today announced the launch of the GSK Vaccines Access Program, which will provide the company's adult vaccines free of charge to eligible, low income individuals who do not have insurance coverage for vaccines. The program will cover the company's FDA-approved vaccines for Hepatitis A, Hepatitis B, tetanus, diphtheria, and pertussis for eligible persons ages 19 and older.

29 Mar 2010

Celerion completes acquisition of MDS Pharma Services' early stage clinical development operations

Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada.

29 Mar 2010

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genmab A/S announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra™ in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

26 Mar 2010

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

The GAVI Alliance on Tuesday formally announced that drugmakers GlaxoSmithKline and Pfizer had signed off on a "10-year deal … to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations," Reuters reports.

25 Mar 2010

GlaxoSmithKline News and Research

POZEN enters Settlement Agreement with Teva over generic Treximet ANDA patent infringement litigation

Opinions divided on swine flu fear

Drug company payments to doctors: Continuing controversy

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Has the NHS procured too many swine flu shots?

Crucell, GSK sign agreement to develop 'second generation malaria vaccine'

Premature fall in the swine flu vaccination rates worries health officials

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

Pfizer admits paying $35 million to doctors over last 6 months

Symyx Technologies forms alliance with Pistoia Alliance

Dutasteride reduces risk of prostate cancer

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

GSK re-submits sNDA for Avodart to FDA

GSK offers free vaccines for low income adults without insurance coverage

Celerion completes acquisition of MDS Pharma Services' early stage clinical development operations

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News